Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Opportunistic gut pathogens are a diverse group of microorganisms, including bacteria like Clostridioides difficile and fungi like Candida albicans, that typically reside harmlessly in the gut but cause disease when the host's internal environment is altered (Nature Reviews Microbiology, 2013). These alterations often stem from antibiotic use, which depletes the protective commensal microbiota, or from host immunosuppression (Cell Host & Microbe, 2016). Once the ecological balance is shifted, these pathogens can rapidly proliferate and deploy virulence factors such as toxins that damage the intestinal epithelium (CDC, 2019). Clinically, they are responsible for a wide range of conditions, from antibiotic-associated diarrhea to life-threatening systemic sepsis (The Lancet Infectious Diseases, 2014). Pharmacological intervention primarily involves targeted or broad-spectrum antimicrobials, though these carry the risk of promoting drug resistance and further dysbiosis (Journal of Clinical Investigation, 2011). Modern therapeutic approaches are increasingly exploring the use of fecal microbiota transplantation (FMT) and defined microbial consortia to restore colonization resistance and suppress these opportunistic populations (New England Journal of Medicine, 2013).
Inhibition of bacterial cell wall synthesis, inhibition of protein synthesis, disruption of DNA replication, and restoration of microbial ecology through competitive exclusion.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Opportunistic gut pathogens.